PD-1 immunotherapy for recurrent or metastatic HNSCC

Lancet. 2019 Nov 23;394(10212):1882-1884. doi: 10.1016/S0140-6736(19)32539-5. Epub 2019 Nov 1.

Authors

Robert L Ferris¹, Lisa Licitra²

Affiliations

¹ UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA 15232, USA. Electronic address: ferrisrl@upmc.edu.
² Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

PMID: 31679948
DOI: 10.1016/S0140-6736(19)32539-5

No abstract available

Publication types

Comment

MeSH terms

Antibodies, Monoclonal, Humanized
Cetuximab
Head and Neck Neoplasms*
Humans
Immunotherapy
Programmed Cell Death 1 Receptor
Squamous Cell Carcinoma of Head and Neck*

Substances

Antibodies, Monoclonal, Humanized
Programmed Cell Death 1 Receptor
pembrolizumab
Cetuximab